Preventive effects of sequential treatment with alendronate and 1α-hydroxyvitamin D3 on bone mass and strength in ovariectomized rats

Bone

Volumn 33, Issue 1, 2003, Pages 90-99

  Ito, M ^a   Azuma, Y ^a   Takagi, H ^a   Kamimura, T ^a   Komoriya, K ^a   Ohta, T ^a   Kawaguchi, H ^b  

^a TEIJIN LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Alendronate; Alfacalcidol; Bisphosphonate; Osteoporosis; Postmenopause; Withdrawal

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; CALCITRIOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRENGTH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FEMUR; HISTOLOGY; LUMBAR VERTEBRA; NONHUMAN; OVARIECTOMY; RAT; TRABECULAR BONE;

EID: 0042624966     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(03)00170-4     Document Type: Article

References (65)

1. Watts N.B. Postmenopausal osteoporosis. Obstet Gynecol Surv. 54:1999;532-538.
2. Prestwood K.M., Pilbeam C.C., Raisz L.G. Treatment of osteoporosis. Annu Rev Med. 46:1995;249-256.
3. Azuma Y., Sato H., Oue Y., Okabe K., Ohta T., Tsuchimoto M., Kiyoki M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models (erratum 1995; 17:333). Bone. 16:1995;235-245.
4. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., Wesolowski G., Russell R.G.G., Rodan G.A., Reszka A.A. Alendronate mechanism of action geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro . Proc Natl Acad Sci USA. 96:1999;133-138.
5. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., Rodan G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 88:1991;2095-2105.
6. Breuil V., Cosman F., Stein L., Horbert W., Nieves J., Shen V., Lindsay R., Dempster D.W. Human osteoclast formation and activity in vitro effects of alendronate . J Bone Miner Res. 13:1998;1721-1729.
7. Schmidt A., Rutledge S.J., Endo N., Opas E.E., Tanaka H., Wesolowski G., Leu C.T., Huang Z., Ramachandaran C., Rodan S.B., Rodan G.A. Protein-tyrosine phosphatase activity regulates osteoclast formation and function inhibition by alendronate . Proc Natl Acad Sci USA. 93:1996;3068-3073.
8. van Beek E.R., Lowik C.W., Papapoulos S.E. Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone. 20:1997;335-340.
9. Sato M., Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 5:1990;31-40.
10. Azuma Y., Oue Y., Kanatani H., Ohta T., Kiyoki M., Komoriya K. Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats comparison with pamidronate and etidronate in growing rats . J Pharmacol Exp Ther. 286:1998;128-135.
11. Seedor J.G., Quartuccio H.A., Thompson D.D. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res. 6:1991;339-346.
12. Toolan B.C., Shea M., Myers E.R., Borchers R.E., Seedor J.G., Quartuccio H., Rodan G., Hayes W.C. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res. 7:1992;1399-1406.
13. Hochberg M.C., Ross P.D., Black D., Cummings S.R., Genant H.K., Nevitt M.C., Barrett-Connor E., Musliner T., Thompson D. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 42:1999;1246-1254.
14. Kanis J.A., Gertz B.J., Singer F., Ortolani S. Rationale for the use of alendronate in osteoporosis. Osteoporos Int. 5:1995;1-13.
15. Shiraki M., Kushida K., Fukunaga M., Kishimoto H., Kaneda K., Minaguchi H., Inoue T., Tomita A., Nagata Y., Nakashima M., Orimo H. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J. 45:1998;191-201.
16. McClung M., Clemmesen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S., Fuleihan G.E.-H., Reda C., Yates A.J., Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med. 128:1998;253-261.
17. Ravn P., Clemmesen B., Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 24:1999;237-244.
18. Ravn P., Weiss S.R., Rodriguez-Portales J.A., McClung M.R., Wasnich R.D., Gilchrist N.L., Sambrook P., Fogelman I., Krupa D., Yates A.J., Daifotis A., Fuleihan G.E. Alendronate in early postmenopausal women effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group . J Clin Endocrinol Metab. 85:2000;1492-1497.
19. Ravn P., Christensen J.O., Baumann M., Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment prediction of bone mass changes during treatment . Bone. 22:1998;559-564.
20. Dawson-Hughes B. Calcium supplementation and bone loss a review of controlled clinical trials . Am J Clin Nutr. 54:1991;274S-280S.
21. Nakamura T. Vitamin D for the treatment of osteoporosis. Osteoporos Int. 7:1997;S155-158.
22. 3 in the pathogenesis and treatment of osteoporosis. Osteoporos Int. 7:1997;S24-29.
23. Gallagher J.C., Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 113:1990;649-655.
24. Tilyard M.W., Spears G.F., Thomson J., Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 326:1992;357-362.
25. 3. Bone. 16:1995;129-135.
26. 3 analogues for the treatment of osteoporosis. Osteoporos Int. 3:1993;190-193.
27. Francis R.M. Is there a differential response to alfacalcidol and vitamin D in the treatment of osteoporosis? Calcif Tissue Int. 60:1997;111-114.
28. Fujita T. Vitamin D in the treatment of osteoporosis. Proc Soc Exp Biol Med. 199:1992;394-399.
29. Menczel J., Foldes J., Steinberg R., Leichter I., Shalita B., Bdolah-Abram T., Kadosh S., Mazor Z., Ladkani D. Alfacalcidol (alphaD3) and calcium in osteoporosis. Clin Orthop. 300:1994;241-247.
30. 3. Bone Miner. 3:1987;47-52.
31. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int. 54:1994;370-376.
32. 3 and estrogen therapy on cortical bone mechanical properties in the ovariectomized rat model. Endocrinology. 137:1996;1358-1364.
33. 3 analogs on osteoporosis caused by ovariectomy in rats. Acta Vitaminol Enzymol. 7:1985;173-181.
34. Shiraishi A., Takeda S., Masaki T., Higuchi Y., Uchiyama Y., Kubodera N., Sato K., Ikeda K., Nakamura T., Matsumoto T., Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis distinct actions from estrogen . J Bone Miner Res. 15:2000;770-779.
35. Gallagher J.C., Jerpbak C.M., Jee W.S., Johnson K.A., DeLuca H.F., Riggs B.L. 1,25-Dihydroxyvitamin D3 short- and long-term effects on bone and calcium metabolism patients with postmenopausal osteoporosis . Proc Natl Acad Sci USA. 79:1982;3325-3329.
36. Nishikawa T., Ogawa S., Kogita K., Manabe N., Katsumata T., Nakamura K., Kawaguchi H. Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone. 27:2000;647-654.
37. 3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol. 89:2002;255-266.
38. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.
39. Ohta T., Azuma Y., Kiyoki M., Eguchi H., Arita M., Hosoda K., Tsukamoto Y., Nakamura T. Measurement of intact rat osteocalcin in osteoblast (ROS17/2.8) cells and in ovariectomized rats with a sandwich enzyme immunoassay. Calcif Tissue Int. 59:1996;283-290.
40. Black D., Duncan A., Robins S.P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem. 169:1988;197-203.
41. Ammann P., Rizzoli R., Slosman D., Bonjour J.P. Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy x-ray absorptiometry. J Bone Miner Res. 7:1992;311-316.
42. Mosekilde L., Danielsen C.C., Knudsen U.B. The effect of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats. Bone. 14:1993;1-6.
43. Mosekilde L., Kragstrup J., Richards A. Compressive strength, ash weight, and volume of vertebral trabecular bone in experimental fluorosis in pigs. Calcif Tissue Int. 40:1987;318-322.
44. Mosekilde L., Sogaard C.H., Danielsen C.C., Torring O. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing a comparison study between hPTH-(1-34) and hPTH-(1-84) . Endocrinology. 129:1991;421-428.
45. Molster A.O. Biomechanical effects of intramedullary reaming and nailing on intact femora in rats. Clin Orthop. 202:1986;278-285.
46. Katsumata T., Nakamura T., Ohnishi H., Sakurama T. Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J Bone Miner Res. 10:1995;921-931.
47. Azuma Y., Ito M., Harada Y., Takagi H., Ohta T., Jingushi S. Low-intensity pulsed ultrasound accelerates rat femoral fracture healing by acting on the various cellular reactions in the fracture callus. J Bone Miner Res. 16:2001;671-680.
48. Schenk R., Eggli P., Fleisch H., Rosini S. Quantitative morphometric evaluation of the inhibitor activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 38:1986;342-349.
49. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R. Bone histomorphometry standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee . J Bone Miner Res. 2:1987;595-610.
50. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., Opas E.E., Seedor J.G., Klein H., Frankenfield D., Quartuccio H., Fioravanti C., Clair J., Brown E., Hayes W.C., Rodan G.A. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 92:1993;2577-2586.
51. Thompson D.D., Seedor J.G., Quartuccio H., Solomon H., Fioravanti C., Davidson J., Klein H., Jackson R., Clair J., Frankenfield D., Brown E., Simmons H.A., Rodan G.A. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res. 7:1992;951-960.
52. Lin J.H., Chen I.W., deLuna F.A. On the absorption of alendronate in rats. J Pharm Sci. 83:1994;1741-1746.
53. Bone H.G., Downs R.W. Jr, Tucci J.R., Harris S.T., Weinstein R.S., Licata A.A., McClung M.R., Kimmel D.B., Gertz B.J., Hale E., Polvino W.J. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab. 82:1997;265-274.
54. Chesnut C.H. 3rd, McClung M.R., Ensrud K.E., Bell N.H., Genant H.K., Harris S.T., Singer F.R., Stock J.L., Yood R.A., Delmas P.D., Kher U. Pryor-Tillotson S, Santora AC. Alendronate treatment of the postmenopausal osteoporotic woman effect of multiple dosages on bone mass and bone remodeling . Am J Med. 99:1995;144-152.
55. Neele S.J., Evertz R., De Valk-De Roo G., Roos J.C., Netelenbos J.C. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in health postmenopausal women. Bone. 30:2002;599-603.
56. Li Q.N., Liang N.C., Huang L.F., Wu T., Hu B., Mo L.E. Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats. J Bone Miner Metab. 17:1999;18-22.
57. Miyakoshi N., Sato K., Tamura Y., Tsuchida T., Kudo T., Kasukawa Y. Evaluation of long-term sequential changes in bone mass and strength following withdrawal of incadronate disodium (YM175) in ovariectomized rats. J Orthop Sci. 6:2001;167-176.
58. Tamura Y., Miyakoshi N., Itoi E., Abe T., Kudo T., Tsuchida T., Kasukawa Y., Sato K. Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats. J Bone Miner Res. 16:2001;541-549.
59. 3 and vitamin D analogues on developmental control of cell growth and tissue-specific expression during osteoblast differentiation. Bioorg Med Chem Lett. 3:1993;1885-1890.
60. Lauritzen D.B., Balena R., Shea M., Seedor J.G., Markatos A., Le H.M., Toolan B.C., Myers E.R., Rodan G.A., Hayes W.C. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J Bone Miner Res. 8:1993;871-879.
61. Delmas P.D., Vergnaud P., Arlot M.E., Pastoureau P., Meunier P.J., Nilssen M.H. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone. 16:1995;603-610.
62. Faulkner K.G. Bone matters are density increases necessary to reduce fracture risk? J Bone Miner Res. 15:2000;183-187.
63. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women the OFELY study . J Bone Miner Res. 15:2000;1526-1536.
64. Melton L.J. 3rd, Khosla S., Atkinson E.J., O'Fallon W.M., Riggs B.L. Relationship of bone turnover to bone density and fractures. J Bone Miner Res. 12:1997;1083-1091.
65. Riggs B.L., Melton L.J. 3rd. Bone turnover matters the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density . J Bone Miner Res. 17:2002;11-14.